

File 410:The Chronolog 1991-2010/ Dec  
(c) 2011 Dialog.

Set	Items	Description
---	-----	-----
? set hi ;set hi		
HILIGHT set on as ''		
HILIGHT set on as ''		
?		
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES		
? 5,73,155,399		
>>>Unrecognizable Command		
? begin 5,73,155,399		
	03mar11 16:31:55	User208760 Session D3249.2
	\$0.00	0.230 DialUnits File410
	\$0.00	Estimated cost File410
	\$2.42	TELNET
	\$2.42	Estimated cost this search
	\$3.03	Estimated total session cost 0.382 DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 5:Biosis Previews(R) 1926-2011/Feb W4  
(c) 2011 The Thomson Corporation  
File 73:EMBASE 1974-2011/Mar 03  
(c) 2011 Elsevier B.V.  
File 155:MEDLINE(R) 1950-2011/Mar 02  
(c) format only 2011 Dialog  
\*File 155: Medline has been reloaded with the 2011 MeSH  
thesaurus.  
File 399:CA SEARCH(R) 1967-2010/UD=15410  
(c) 2011 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set	Items	Description
---	-----	-----
? s (bb5(w)1)(20n)(antibod?)(20n)(c5?)		
Processing		
	102	BB5
	16082561	1
	2800427	ANTIBOD?
	419827	C5?
S1	19	(BB5(W)1)(20N)(ANTIBOD?)(20N)(C5?)
? rd s1		
S2	9	RD S1 (unique items)
? s s2 and (conversion or convertase)		
	9	S2
	521150	CONVERSION
	13311	CONVERTASE
S3	1	S2 AND (CONVERSION OR CONVERTASE)
? t s3/7/all		

3/7/1 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2011 Elsevier B.V. All rts. reserv.

0080685483 EMBASE/Medline No: 2005329801  
Strategies of therapeutic complement inhibition  
ISSUE TITLE: 10th Meeting on Complement in Human Disease  
Mollnes T.E.; Kirschfink M.

Institute of Immunology, Rikshospitalet University Hospital, University  
of Oslo, N-0027 Oslo, Norway  
AUTHOR EMAIL: t.e.mollnes@labmed.uio.no  
CORRESP. AUTHOR/AFFIL: Mollnes T.E.: Institute of Immunology,  
Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway  
CORRESP. AUTHOR EMAIL: t.e.mollnes@labmed.uio.no

Molecular Immunology ( Mol. Immunol. ) (United Kingdom) January 1, 2006  
, 43/1-2 (107-121)  
CODEN: IMCHA ISSN: 0161-5890  
PUBLISHER ITEM IDENTIFIER: S0161589005002075  
DOI: 10.1016/j.molimm.2005.06.014  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 184

The involvement of complement in the pathogenesis of a great number of  
partly life threatening diseases defines the importance to develop  
inhibitors which specifically interfere with its deleterious action.  
Endogenous soluble complement-inhibitors, antibodies or low molecular  
weight antagonists, either blocking key proteins of the cascade reaction or  
neutralizing the action of the complement-derived anaphylatoxins have  
successfully been tested in various animal models over the past years.  
Promising results consequently led to first clinical trials. This review is  
focused on different approaches for the development of inhibitors, on their  
site of action in the cascade, on possible indications for complement  
inhibition based on experimental animal data, and on potential side effects  
of such treatment. (c) 2005 Elsevier Ltd. All rights reserved.

? t s3/7/kwic  
>>>'KWIC' not recognized as item list  
? t s3/kwic/all  
>>>KWIC option is not available in file(s): 399

3/KWIC/1 (Item 1 from file: 73)  
DIALOG(R)File 73:(c) 2011 Elsevier B.V. All rts. reserv.

#### DRUG DESCRIPTORS:

...agent--drug therapy--dt; aprotinin; CD59 antigen--drug therapy--dt;  
classical complement pathway C3 C5 convertase--endogenous compound  
--ec; complement component C1s inhibitor--drug therapy--dt; complement  
component C5 inhibitor--clinical...

#### MEDICAL DESCRIPTORS:

DRUG TERMS (UNCONTROLLED): apt 070--drug therapy--dt; complement component  
c5 antibody--drug therapy--dt; complement component c5  
antibody--pharmacology--pd; complement component c5a  
antibody--pharmacology--pd; complement component c8 antibody  
--pharmacology--pd; complement receptor 1 related protein--drug therapy--dt  
; complement receptor 1 related protein--pharmacology--pd; monoclonal  
\*\*\*antibody\*\*\* \*\*\*bb5\*\*\* . \*\*\*1\*\*\* --drug therapy--dt; monoclonal  
\*\*\*antibody\*\*\* \*\*\*bb5\*\*\* . \*\*\*1\*\*\* --pharmacology--pd; recombinant  
complement  
component C3b receptor--drug comparison--cm; recombinant complement  
component C3b receptor...  
...CAS REGISTRY NO.: 9087-70-1 (aprotinin); 56626-15-4 (classical  
complement pathway C3 C5 \*\*\*convertase\*\*\* ); 80295-37-0...

?